(Reuters) - Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove .
Tracking Baker Brothers Portfolio – Q3 2023 Update seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a mid-stage study. The therapy, RP1, in combination…
Replimune Group Inc. shares dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet.